LMDXF
NASDAQ: LMDXF (LumiraDx Limited)
Last update: 2 hours ago0.010
0.01 (100.00%)
| Previous Close | 0.005 |
| Open | 0.000 |
| Volume | 7,433 |
| Avg. Volume (3M) | 48,002 |
| Market Cap | 246,507,008 |
| Price / Sales | 0.010 |
| Price / Book | 18.28 |
| 52 Weeks Range | |
| Earnings Date | 25 Oct 2024 - 29 Oct 2024 |
| Profit Margin | -267.19% |
| Operating Margin (TTM) | -231.44% |
| Diluted EPS (TTM) | -1.08 |
| Quarterly Revenue Growth (YOY) | -53.00% |
| Current Ratio (MRQ) | 0.450 |
| Operating Cash Flow (TTM) | -129.71 M |
| Levered Free Cash Flow (TTM) | -54.01 M |
| Return on Assets (TTM) | -28.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | LumiraDx Limited | - | - |
Stockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 37.93% |
| % Held by Institutions | 3.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Xtx Topco Ltd | 30 Jun 2024 | 0 |
| Bill & Melinda Gates Foundation | 30 Jun 2024 | 0 |
| Hyman Charles D | 30 Jun 2024 | 0 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |